MRKR Marker Therapeutics
- 4.2400
- -0.0500-1.17%
Marker Therapeutics News
Marker Therapeutics' MT-601 Shows Promising Results
Marker Therapeutics Advances in Immuno-Oncology
Marker Therapeutics GAAP EPS of -$1.59, Revenue of $3.31M
Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter o
Press Release: Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response
Marker Therapeutics Ends Stock Sale Deal With LPC
Marker Therapeutics Receives Approval From United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).
Marker Therapeutics Says 'MultiTAA-specific T Cell Therapies Demonstrate Clinical Safety and Positive Clinical Data Across Multiple Indications'
Marker Therapeutics Says 'MultiTAA-specific T Cell Therapies Demonstrate Clinical Safety and Positive Clinical Data Across Multiple Indications'
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics Announces Clinical Program Updates And Pipeline Prioritization
Marker Therapeutics Announces Clinical Program Updates And Pipeline Prioritization
12 Health Care Stocks Moving In Friday's After-Market Session
GainersStrata Skin Sciences (NASDAQ:SSKN) shares moved upwards by 60.0% to $0.88 during Friday's after-market session. The company's market cap stands at $30.8 million. Cue Health (NASDAQ:HLTH) shares
Palatin Technologies, Cellectis Among Healthcare Movers
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During "J.P. Morgan Week 2024"
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of
PSTX, MRKR and GPRO Among Pre-market Losers
Top Midday Gainers
Marker Therapeutics (MRKR) said the "sustained complete response in our first patient treated with MT-601 over six months has been an encouraging and rewarding experience" in the phase 1 study. The "r
GTHX, MRKR and CLIR Among Mid-day Movers
12 Health Care Stocks Moving In Monday's Intraday Session
GainersPasithea Therapeutics (NASDAQ:KTTA) stock increased by 105.9% to $0.62 during Monday's regular session. The company's market cap stands at $12.8 million. Assure Hldgs (NASDAQ:IONM) stock moved
Marker Therapeutics Shares Rise on Positive MT-601 Update
By Dean Seal Shares of Marker Therapeutics advanced after the company reported a sustained complete response in its first lymphoma patient treated with MT-601. The stock was up 8.5% at $3.48 in earl
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated With MT-601 Following CAR T Relapse
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of
Analysis
Price Target
No Data
